Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Julian I, Iwamoto T. Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats. Biol Pharm Bull 2021;44:1050-1059. [PMID: 34334490 DOI: 10.1248/bpb.b21-00112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]

For:	Julian I, Iwamoto T. Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats. Biol Pharm Bull 2021;44:1050-1059. [PMID: 34334490 DOI: 10.1248/bpb.b21-00112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]

Number	Cited by Other Article(s)
1	Jovičić S, Gajanin V, Umičević-Šipka S. Cutaneous side effects during therapy with Erlotinib: Case report. SCRIPTA MEDICA 2021. [DOI: 10.5937/scriptamed52-35385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open Abstract Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented. Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Jovičić S, Gajanin V, Umičević-Šipka S. Cutaneous side effects during therapy with Erlotinib: Case report. SCRIPTA MEDICA 2021. [DOI: 10.5937/scriptamed52-35385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open